Table 5.
PEA | Placebo | |||||
---|---|---|---|---|---|---|
Baseline | Week 4 | Week 8 | Baseline | Week 4 | Week 8 | |
Sleep time (hrs) | 6.1 ± 1.5 | 6.7 ± 1.4 | 6.7 ± 1.3 | 6.1 ± 1.5 | 6.5 ± 1.3 | 6.5 ± 1.5 |
Sleep Latencya (min) | 42.8 ± 42.2 | 26.8 ± 26.3* | 23.4 ± 23.1* | 36.2 ± 40.5 | 34.2 ± 40.5 | 30.3 ± 39.2 |
Interruptions (n) | 3.3 ± 2.1 | 3.0 ± 2.3 | 3.3 ± 3.0 | 3.9 ± 3.8 | 3.0 ± 3.0 | 2.9 ± 2.8 |
Interruptions (min) | 41.0 ± 39.3 | 29.9 ± 30.1 | 35.0 ± 34.8 | 35.3 ± 32.0 | 31.6 ± 41.5 | 32.6 ± 42.7 |
N.B. Data presented as mean ± standard deviation; * = significant difference between groups; a sleep latency data for participants reporting > 10 min at baseline (n = 78); PEA Palmitoylethanolamide